Loading...
Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma
Muszbek, N. Remak, E. Evans, R. Brennan, V. K. Colaone, F. Shergill, S. Mullan, Damian Ross, P. J.
Muszbek, N.
Remak, E.
Evans, R.
Brennan, V. K.
Colaone, F.
Shergill, S.
Mullan, Damian
Ross, P. J.
Citations
Altmetric:
Abstract
Background: The study assessed the cost-utility of selective internal radiation therapy (SIRT) with Y-90 resin microspheres versus sorafenib in UK patients with unresectable hepatocellular carcinoma ineligible for transarterial chemoembolization. Materials & methods: A lifetime partitioned survival model was developed for patients with low tumor burden (≤25%) and good liver function (albumin-bilirubin grade 1). Efficacy, safety and quality of life data were from a European Phase III randomized controlled trial and published studies. Resource use was from registries and clinical surveys. Results: Discounted quality-adjusted life-years were 1.982 and 1.381, and discounted total costs were £29,143 and 30,927, for SIRT and sorafenib, respectively. Conclusion: SIRT has the potential to be a dominant (more efficacious/less costly) or cost-effective alternative to sorafenib in patients with unresectable hepatocellular carcinoma.
Affiliation
Description
Date
2020
Publisher
Collections
Files
Loading...
From UNPAYWALL
Adobe PDF, 1.63 MB
Keywords
Type
Article
Citation
Muszbek N, Remak E, Evans R, Brennan VK, Colaone F, Shergill S, et al. Cost-utility analysis of selective internal radiation therapy with Y-90 resin microspheres in hepatocellular carcinoma. Future Oncol. 2020.